The PWS Nanocytology Platform
Cancer is caused by an uncontrolled division of abnormal (mutated) cells in a part of the body. The current gold-standard approach to diagnose cancer is to send biopsied cells to a lab, where a pathologist looks for cellular changes at the microscopic (“micro”) level. Preora’s proprietary, automated technology platform, Partial Wave Spectroscopy (PWS) Nanocytology, examines cells at the nanoscale (“nano”) level, where mutations and cellular changes can be detected long before they are evident at the micro level.
In fact, cells may appear to be normal to technicians using standard microscopy, but PWS can detect profound changes in the nanoscale architecture of the same cells. PWS measures the disorder strength of the nanoscale organization of the cell, which the Preora team has determined to be one of the earliest signs of carcinogenesis, likely making it a strong and clinically significant biomarker for the presence of cancer. PWS enables a paradigm shift, in that we don’t need to examine the tumor itself to stratify the cancer risk for an individual patient. (See Field Effect below for why surrogate cells are clinically relevant in cancer).
Preora’s long-term goal is to develop the PWS platform to serve as a highly accurate, low-cost, non-invasive testing to identify which patients are likely to benefit from gold-standard cancer diagnostic procedures.